Horizon Kinetics Medical ETF (MEDX)

The Horizon Kinetics Medical ETF is an actively managed exchange-traded fund that holds a portfolio of healthcare companies. Unlike index-tracking ETFs that mechanically follow a preset list, MEDX is run by human portfolio managers who pick individual healthcare stocks they believe offer value — companies in pharmaceuticals, medical devices, biotechnology, healthcare providers, and related services. The fund trades on exchanges like a regular stock but with the legal structure of a fund, giving investors the ability to gain diversified exposure to healthcare through a single holding.

Healthcare investing has distinctive cycles tied to drug approvals, patent cliffs (when blockbuster drugs lose patent protection and face generic competition), regulatory changes, and shifts in reimbursement policy. The fund’s active management is premised on the belief that skilled stock-picking can navigate these cycles better than a passive index approach.

What the fund holds

MEDX invests across the healthcare landscape. Holdings typically include large pharmaceutical manufacturers, smaller biotech companies developing new drugs, makers of medical devices and diagnostics, and healthcare service providers such as pharmacy benefit managers, clinical laboratories, and contract research organizations. The fund does not concentrate in a single therapeutic area — it holds companies across oncology, rare diseases, cardiology, vaccines, and other treatment domains.

Because the fund is actively managed, its exact holdings change as the portfolio managers’ views shift. Unlike an index fund, which holds the same companies as long as they remain in the underlying index, MEDX’s composition reflects the managers’ conviction about which healthcare firms are mispriced or best positioned for coming cycles. This flexibility is both the appeal and the risk: the fund can outperform if the managers’ bets play out, but it can also underperform if their picks do not.

The cyclical nature of healthcare

Healthcare companies behave differently across economic cycles than many other stocks. A severe recession may actually benefit pharmaceutical and medical-device makers, because people still need drugs and procedures even when the broader economy weakens. But healthcare has its own cycles driven by science and regulation rather than the economy alone: a major drug approval can lift a company’s stock for years, while a patent expiration can create a sharp decline almost overnight.

Pharmaceutical revenues depend heavily on the patent-protected period for each drug. A company’s growth engine slows when its blockbuster drugs face generic competition — the generic typically captures the market within a year of approval. To offset these cliffs, pharmaceutical companies must have new drugs in their pipeline approaching approval, or they must make acquisitions to replenish their revenue base. Some cycles are predictable based on patent calendars; others hinge on the outcome of clinical trials that may not be known for years.

Medical-device companies tend to be more stable than pharmaceutical makers, because devices often enjoy longer competitive advantages through regulatory hurdles (FDA approval is lengthy and expensive to replicate), and they are less vulnerable to generic competition. However, device companies face their own cyclicality: spending on elective procedures drops when patients lack money or confidence, and healthcare providers face pressure during downturns to reduce capital spending.

Costs, liquidity, and structure

The fund carries an expense ratio that reflects its active management. Active ETFs are more expensive to run than passive index funds — the managers are paid to research and pick stocks, and those costs show up in the expense ratio. For healthcare investing, the cost is justified by some investors as worth paying if the managers’ stock-picking adds value, but it is also a headwind against performance that must be overcome.

MEDX trades on an exchange during regular market hours, like any stock, with intraday liquidity. This means investors can buy or sell shares whenever the market is open, rather than waiting for a daily pricing update as with traditional mutual funds. The bid-ask spread (the difference between the buying and selling price at any moment) is typically tight for established healthcare ETFs, though it can widen during periods of market stress or if trading volume dries up.

The fund uses a standard ETF wrapper, which has tax-efficiency advantages. Redemptions and creations of new fund shares are handled through in-kind transactions that minimize taxable distributions to remaining shareholders. For long-term holders in taxable accounts, this structure can mean lower annual tax drag than a traditional actively managed mutual fund.

Risks specific to healthcare funds

Healthcare investing carries sector-specific risks beyond normal market volatility. Regulatory and clinical outcomes are binary: a drug that is close to approval will either get it or not; a therapy that seems promising based on early data might fail in late-stage trials. These events can move a stock 30 percent or more in a single day, and a fund holding the affected company will experience that same move.

Reimbursement risk is also significant. If a government healthcare program or major insurance company decides a drug is too expensive and will not pay for it, demand collapses regardless of the drug’s efficacy. This has happened repeatedly in the real world, making pharmaceutical companies vulnerable to decisions outside their control.

For MEDX specifically, the active-management risk is that the portfolio managers may simply make poor stock picks. If their conviction bets underperform the overall healthcare sector, shareholders bear the cost of higher fees for below-index returns — the worst outcome for an active fund.

Who MEDX is for and how to research it

MEDX suits investors who believe healthcare will outperform the broader market and want to tilt their portfolio in that direction, but who prefer active management to picking individual healthcare stocks. It also appeals to investors who want diversified healthcare exposure but are skeptical that a passive index best captures healthcare value.

To understand the fund, start with its prospectus and fact sheet, which detail the fund’s investment strategy, fee structure, and top holdings. Because MEDX is actively managed, track the fund’s holdings over time to see what bets the managers are making — and research the portfolio managers’ track records before investing: do they have a long history beating the healthcare benchmark?

Watch the performance of the fund relative to a healthcare index benchmark (such as the broader healthcare equity index) over multiple years. A single year of outperformance proves nothing, but sustained outperformance net of fees indicates genuine skill. Also monitor the fund’s expense ratio relative to other actively managed healthcare ETFs, and check the fund’s cash holdings and cash flow patterns — high cash drag can signal that managers are unsure of opportunities in the market.